Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis AG

www.novartis.com

Latest From Novartis AG

Rybelsus, Other Treatment Improvements For Chronic Disease Have OptumRx’s Attention

UnitedHealthcare’s pharmacy benefit manager highlights potential cost pressures from upcoming novel or improved treatments for diabetes, wet AMD, HIV and migraine, as well as luspatercept for beta thalassemia, in its latest pipeline report.

Pricing Strategies Reimbursement

EMA OKs Seven New Drugs But Delivers Another Blow To Emmaus

Seven new drugs have this week moved closer to gaining EU approval following positive recommendations from the European Medicines Agency, but Emmaus’ glutamine product has fared less well and the company is considering another route for getting the drug to sickle cell disease patients in Europe

Europe Drug Review

Gene Profiling Identifies Drugs For Childhood Cancers But Access A Problem

Lack of infrastructure for identifying mutations and access routes is holding back use of targeted medicines in children with cancer

Cancer Personalized Medicine

Emmaus Fumes After EMA Rejects Sickle Cell Drug Again

The US firm has withdrawn its submission to get EU approval for Xyndari. After being turned down by the CHMP, Emmaus may try the decentralized approval procedure instead.

Drug Review Blood & Coagulation Disorders
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register